PriceTargets.com logo

Sagimet Biosciences - SGMT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $27.96
  • Forecasted Upside: 165.82%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$10.52 As of 09/16/2026 12:54 PM ET
▲ +0.058 (0.55%)

This chart shows the closing price for SGMT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sagimet Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGMT

Analyst Price Target is $27.96
▲ +165.82% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Sagimet Biosciences in the last 3 months. The average price target is $27.96, with a high forecast of $56.00 and a low forecast of $10.71. The average price target represents a 165.82% upside from the last price of $10.52.

This chart shows the closing price for SGMT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 contributing investment analysts is to moderate buy stock in Sagimet Biosciences. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/18/2026
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/17/2026
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/16/2026

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/9/2026Cantor FitzgeraldInitiated CoverageOverweight$10.71
9/9/2026BarclaysUpgradeEqual Weight ➝ Overweight$8.00 ➝ $18.00
9/9/2026Cantor FitzgeraldInitiated CoverageOverweight$10.71
8/25/2026HC WainwrightReiterated RatingBuy ➝ Buy$29.00
8/14/2026CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
8/14/2026Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$12.00 ➝ $29.00
8/12/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$49.00 ➝ $56.00
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
5/19/2026Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$35.00 ➝ $12.00
5/4/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$28.00 ➝ $49.00
5/1/2026OppenheimerReiterated RatingOutperform ➝ Outperform
4/29/2026GuggenheimLower TargetBuy ➝ Buy$27.00 ➝ $25.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/26/2026Rodman & RenshawInitiated CoverageBuy$28.00
3/11/2026HC WainwrightReiterated RatingBuy ➝ Buy$29.00
2/3/2026HC WainwrightReiterated RatingBuy ➝ Buy$29.00
2/3/2026GuggenheimInitiated CoverageBuy$27.00
1/27/2026BarclaysInitiated CoverageEqual Weight$8.00
1/27/2026BarclaysUpgradeHold
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/14/2025CitigroupReiterated RatingOutperform ➝ Outperform
11/14/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $35.00
11/12/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
10/14/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/2/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$28.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/11/2025WedbushInitiated CoverageOutperform$28.00
8/7/2025HC WainwrightUpgradeBuy$29.00
7/24/2025Canaccord Genuity GroupInitiated CoverageBuy$28.00
6/6/2025JonesTradingBoost TargetBuy ➝ Buy$15.00 ➝ $27.00
3/11/2025HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
12/6/2024OppenheimerInitiated CoverageOutperform$30.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
11/12/2024UBS GroupInitiated CoverageBuy$12.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
10/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
8/15/2024Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$48.00 ➝ $32.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
6/28/2024The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$23.00 ➝ $6.00
6/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
6/7/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$48.00 ➝ $48.00
6/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
5/24/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$48.00 ➝ $48.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
5/16/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$27.00 ➝ $23.00
5/2/2024HC WainwrightInitiated CoverageBuy$32.00
3/26/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$37.00 ➝ $27.00
3/25/2024Leerink PartnersReiterated RatingOutperform
3/25/2024Leerink PartnersInitiated CoverageOutperform$26.00
2/7/2024Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$47.00 ➝ $46.00
1/23/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$30.00 ➝ $37.00
1/22/2024Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$31.00 ➝ $47.00
12/5/2023Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$31.00
8/8/2023TD CowenInitiated CoverageOutperform
8/8/2023Piper SandlerInitiated CoverageOverweight$67.00
8/8/2023The Goldman Sachs GroupInitiated CoverageBuy$33.00
8/8/2023Citizens JmpInitiated CoverageOutperform$30.00
(Data available from 9/16/2021 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 6 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 6 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Sagimet Biosciences logo
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $10.52
Low: $10.42
High: $10.62

50 Day Range

MA: $9.12
Low: $7.01
High: $11.06

52 Week Range

Now: $10.52
Low: $4.50
High: $11.45

Volume

117,766 shs

Average Volume

1,154,708 shs

Market Capitalization

$653.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Sagimet Biosciences?

The following Wall Street analysts have issued research reports on Sagimet Biosciences in the last year: Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Citizens Jmp, Guggenheim, HC Wainwright, Oppenheimer Holdings, Inc., Rodman & Renshaw, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for SGMT.

What is the current price target for Sagimet Biosciences?

0 Wall Street analysts have set twelve-month price targets for Sagimet Biosciences in the last year. Their average twelve-month price target is $27.96, suggesting a possible upside of 167.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting SGMT will reach $56.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $10.71 for Sagimet Biosciences in the next year.
View the latest price targets for SGMT.

What is the current consensus analyst rating for Sagimet Biosciences?

Sagimet Biosciences currently has 1 sell rating, 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SGMT.

What other companies compete with Sagimet Biosciences?

Other companies that are similar to Sagimet Biosciences include Nurix Therapeutics, NewAmsterdam Pharma, Pharvaris, Precigen and Viridian Therapeutics. Learn More about companies similar to Sagimet Biosciences.

How do I contact Sagimet Biosciences' investor relations team?

Sagimet Biosciences' physical mailing address is 950 Tower Lane, Ste 1500, Foster City, CA, 94404. The company's listed phone number is 650-561-8600 and its investor relations email address is [email protected]. The official website for Sagimet Biosciences is sagimet.com. Learn More about contacing Sagimet Biosciences investor relations.